Su Hyun Chae1,2, Chulmin Lee3, Sang Hee Yoon4, Seung Hyuk Shim1, Sun Joo Lee1, Soo Nyung Kim1, Sochung Chung5, Ji Young Lee6. 1. Department of Obstetrics and Gynecology, Konkuk Medical Center, Konkuk University School of Medicine, Seoul, Korea. 2. Department of Obstetrics and Gynecology, Korea University Anam Medical Center, Korea University College of Medicine, Seoul, Korea. 3. Department of Obstetrics and Gynecology, Cha University Ilsan Medical Center, Goyang, Korea. 4. Department of Obstetrics and Gynecology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea. 5. Department of Pediatrics, Konkuk Medical Center, Konkuk University School of Medicine, Seoul, Korea. 6. Department of Obstetrics and Gynecology, Konkuk Medical Center, Konkuk University School of Medicine, Seoul, Korea. jylee@kuh.ac.kr.
Abstract
BACKGROUND: To identify sarcopenia as a predictive prognostic factor of ovarian cancer in terms of survival outcome in patients with early-stage ovarian cancer. METHODS: Data of Konkuk University Medical Center from March 2002 to December 2017 were reviewed retrospectively. Eighty-two patients who underwent surgery due to early-stage (International Federation of Gynecology and Obstetrics stage I/II) ovarian cancer and had computed tomography (CT) images taken at the initial diagnosis were included. The initial CT scan images were analyzed with SliceOmatic software (TomoVision). A sarcopenia cutoff value was defined as a skeletal muscle index of ≤ 38.7 cm²/m². Overall survival (OS) times were compared according to the existence of sarcopenia, and subgroup analyses were performed. RESULTS: A Kaplan-Meier analysis showed a significant survival disadvantage for patients with early-stage ovarian cancer when they had sarcopenia (P < 0.001; log-rank test). Sarcopenia remained a significant prognostic factor for OS in early-stage ovarian cancer, in a Cox proportional hazards model regression analysis (HR, 21.9; 95% CI, 2.0-199.9; P = 0.006). CONCLUSION: This study demonstrated that sarcopenia was predictive of OS in patients with early-stage ovarian cancer. Further prospective studies with a larger number of patients are warranted to determine the extent to which sarcopenia can be used as a prognostic factor in ovarian cancer.
BACKGROUND: To identify sarcopenia as a predictive prognostic factor of ovarian cancer in terms of survival outcome in patients with early-stage ovarian cancer. METHODS: Data of Konkuk University Medical Center from March 2002 to December 2017 were reviewed retrospectively. Eighty-two patients who underwent surgery due to early-stage (International Federation of Gynecology and Obstetrics stage I/II) ovarian cancer and had computed tomography (CT) images taken at the initial diagnosis were included. The initial CT scan images were analyzed with SliceOmatic software (TomoVision). A sarcopenia cutoff value was defined as a skeletal muscle index of ≤ 38.7 cm²/m². Overall survival (OS) times were compared according to the existence of sarcopenia, and subgroup analyses were performed. RESULTS: A Kaplan-Meier analysis showed a significant survival disadvantage for patients with early-stage ovarian cancer when they had sarcopenia (P < 0.001; log-rank test). Sarcopenia remained a significant prognostic factor for OS in early-stage ovarian cancer, in a Cox proportional hazards model regression analysis (HR, 21.9; 95% CI, 2.0-199.9; P = 0.006). CONCLUSION: This study demonstrated that sarcopenia was predictive of OS in patients with early-stage ovarian cancer. Further prospective studies with a larger number of patients are warranted to determine the extent to which sarcopenia can be used as a prognostic factor in ovarian cancer.
Authors: Anlan Cao; Brenda Cartmel; Fang-Yong Li; Linda T Gottlieb; Maura Harrigan; Jennifer A Ligibel; Radhika Gogoi; Peter E Schwartz; Melinda L Irwin; Leah M Ferrucci Journal: J Cancer Surviv Date: 2022-04-04 Impact factor: 4.062
Authors: Stephanie Stelten; Christelle Schofield; Yvonne A W Hartman; Pedro Lopez; Gemma G Kenter; Robert U Newton; Daniel A Galvão; Meeke Hoedjes; Dennis R Taaffe; Luc R C W van Lonkhuijzen; Carolyn McIntyre; Laurien M Buffart Journal: Cancers (Basel) Date: 2022-09-20 Impact factor: 6.575